Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epi-Rad90 Ophthalmic System + ranibizumab
- Development stage
- Unknown
- Lead developer
- ARS Pharmaceuticals
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Ophthalmic, Intravitreal, Intraocular (device Placed During Surgery)
01
Overview
Epi-Rad90 Ophthalmic System + ranibizumab is a combination therapy for the treatment of neovascular (wet) age-related macular degeneration (AMD). The Epi-Rad90 Ophthalmic System is a device that delivers focal strontium-90 (Sr-90) beta radiation directly to the area of the retina affected by choroidal neovascularization, usually after a vitrectomy. This is combined with intravitreal injection of ranibizumab, an anti-vascular endothelial growth factor A (VEGF-A) monoclonal antibody fragment that inhibits abnormal blood vessel growth and leakage in the eye. This combination aims to improve outcomes in wet AMD by combining the antiangiogenic effects of ranibizumab with localized radiation to inhibit neovascular tissue[1][5].
- Brand names
- Lucentis
- Other names
- Epi-Rad90 Ophthalmic System plus ranibizumabEpi-Rad-90 Ophthalmic System plus ranibizumabEpi-Rad 90 Ophthalmic System plus ranibizumabEpi-Rad90 + ranibizumab
02
Targets
Beyond the preview
Go deeper on Epi-Rad90 Ophthalmic System + ranibizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epi-Rad90 Ophthalmic System + ranibizumab.